hereditary-spastic-paraplegia

Hereditary Spastic Paraplegia (HSP)

Introduction

Hereditary Spastic Paraplegia (Hsp) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Hereditary spastic paraplegia (HSP), also known as familial spastic paraparesis (FSP) or Strümpell-Lorrain disease, is a clinically and genetically heterogeneous group of inherited neurodegenerative disorders characterized by progressive spasticity and weakness of the lower limbs due to length-dependent degeneration of the corticospinal tract axons. The pathological hallmark is a "dying-back" axonopathy: the longest motor axons in the corticospinal tract (those projecting to the lumbar spinal cord) degenerate from their distal ends, producing the characteristic pattern of lower extremity spasticity while initially sparing shorter axons. [@blackstone2018]

...

Hereditary Spastic Paraplegia (HSP)

Introduction

Hereditary Spastic Paraplegia (Hsp) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Hereditary spastic paraplegia (HSP), also known as familial spastic paraparesis (FSP) or Strümpell-Lorrain disease, is a clinically and genetically heterogeneous group of inherited neurodegenerative disorders characterized by progressive spasticity and weakness of the lower limbs due to length-dependent degeneration of the corticospinal tract axons. The pathological hallmark is a "dying-back" axonopathy: the longest motor axons in the corticospinal tract (those projecting to the lumbar spinal cord) degenerate from their distal ends, producing the characteristic pattern of lower extremity spasticity while initially sparing shorter axons. [@blackstone2018]

HSP has an estimated global prevalence of 1.2–9.6 per 100,000 individuals, with approximately 80 causative genes identified to date, designated as spastic paraplegia gene (SPG) loci 1–86+. The disorder is classified by inheritance pattern (autosomal dominant, autosomal recessive, X-linked, or mitochondrial) and by clinical phenotype: pure (uncomplicated) HSP presents with isolated spastic paraparesis, while complex (complicated) HSP features additional neurological or systemic manifestations including cognitive impairment, cerebellar ataxia, peripheral neuropathy, epilepsy, or thin [corpus-callosum. The most common form is SPG4 (mutations in SPAST encoding spastin), accounting for 40–45% of autosomal dominant cases. [@schle2016]

--- [@hedera]

Epidemiology

• Prevalence: 1.2–9.6 per 100,000 depending on population and ascertainment methods. Estimated global incidence rate of 3.6 per 100,000.
• Inheritance distribution:
• Autosomal dominant (AD-HSP): 75–80% of registered cases in European populations
• Autosomal recessive (AR-HSP): More common in consanguineous populations (North Africa, Middle East, South Asia)
• X-linked: Rare (<5%)
• De novo mutations: Increasingly recognized with expanded [genetic-testing](/diagnostics/genetic-testing)
• Age at onset: Highly variable — from infancy to the 7th decade. Bimodal distribution with peaks in the 1st decade (childhood-onset forms) and 3rd–4th decades (adult-onset forms).
• Most common subtypes: SPG4 (40–45% of AD-HSP), SPG3A (~10% of AD-HSP), SPG11 (18% globally, most common AR-HSP).

--- [@ruano2014]

Genetics

Classification by Gene

HSP exhibits extraordinary genetic heterogeneity, with over 80 SPG loci identified. The major subtypes include: [@awuah2024]

Autosomal Dominant HSP

| Subtype | Gene | Protein | Prevalence | Key Features | [@stevanin2007]
|---------|------|---------|------------|--------------| [@denton2014]
| SPG4 | SPAST | Spastin | 40–45% of AD-HSP | Pure HSP; AAA-ATPase involved in microtubule severing; most common overall | [@ebrahimifakhari2024]
| SPG3A | ATL1 | Atlastin-1 | ~10% of AD-HSP | Often childhood onset; ER membrane shaping GTPase | [@hazan1999]
| SPG31 | REEP1 | REEP1 | ~5% of AD-HSP | Pure HSP; ER-mitochondria contacts | [@klebe2012]
| SPG10 | KIF5A | Kinesin heavy chain | ~3% of AD-HSP | Pure or complex; axonal transport motor protein | [@hirst2015]
| SPG6 | NIPA1 | NIPA1 | Rare | Endosomal trafficking |

Autosomal Recessive HSP

| Subtype | Gene | Protein | Features |
|---------|------|---------|----------|
| SPG11 | SPG11 | Spatacsin | Most common AR-HSP (18% globally); complex with thin corpus callosum, cognitive impairment |
| SPG15 | ZFYVE26 | Spastizin | Complex with thin corpus callosum; clinically similar to SPG11 |
| SPG7 | SPG7 | Paraplegin | Mitochondrial AAA-protease; pure or complex with cerebellar ataxia |
| SPG5 | CYP7B1 | Oxysterol 7α-hydroxylase | Pure HSP; lipid metabolism |
| SPG35 | FA2H | Fatty acid 2-hydroxylase | Complex with iron accumulation (nbia overlap) |
| SPG47-50 | AP4B1/AP4M1/AP4E1/AP4S1 | AP-4 complex subunits | AP-4 HSP: severe, early onset, intellectual disability, thin CC |

X-Linked HSP

| Subtype | Gene | Protein | Features |
|---------|------|---------|----------|
| SPG1 | L1CAM | L1 cell adhesion molecule | Complex with hydrocephalus, intellectual disability |
| SPG2 | PLP1 | Proteolipid protein 1 | Overlaps with pelizaeus-merzbacher-disease |

Genotype-Phenotype Correlations

• Pure HSP: Most commonly associated with SPG4, SPG3A, SPG31, SPG6
• Complex HSP with thin corpus callosum: SPG11, SPG15, SPG47-50
• HSP with cerebellar ataxia: SPG7, SPG46
• HSP with peripheral neuropathy: SPG3A, SPG10, SPG30
• HSP with cognitive impairment: SPG11, SPG15, SPG21, SPG47-50

Pathophysiology

Core Mechanism: Length-Dependent Axonopathy

The pathological hallmark of HSP is selective, progressive degeneration of the longest axons in the corticospinal tract — specifically, the distal portions of axons projecting from cortical layer 5 pyramidal neurons/cell-types/cortical-pyramidal-l5) in the motor [cortex to the lumbar spinal cord (reaching lengths >1 meter). This "dying-back" pattern produces the characteristic clinical phenotype of lower limb spasticity while upper limbs are initially spared. Similar length-dependent degeneration can affect the dorsal columns (posterior column dysfunction) and spinocerebellar tracts.

Converging Cellular Pathways

Despite genetic heterogeneity, HSP genes converge on a limited number of interconnected cellular pathways, reflecting the unique vulnerability of long corticospinal axons to disruptions in:

Microtubule dynamics and axonal transport

• Spastin (SPG4): An AAA-ATPase that severs microtubules, regulating microtubule dynamics essential for axonal-transport-defects. Loss of microtubule severing impairs transport and organelle distribution in long axons.
• KIF5A (SPG10): A kinesin motor protein directly mediating anterograde axonal transport.
• HSP mutations disrupt the delivery of mitochondria, ER, endosomes, and signaling molecules along extremely long axons.

Endoplasmic reticulum (ER) morphogenesis

• Atlastin-1 (SPG3A), REEP1 (SPG31), reticulon 2 (SPG12): Shape the tubular ER network that extends throughout axons.
• The axonal ER is a continuous organelle network spanning the full length of corticospinal axons. Disrupted ER tubule formation impairs calcium homeostasis, lipid synthesis, and er-mitochondria-contact-sites.

Endolysosomal and autophagymechanisms/autophagy) pathways

• Spatacsin (SPG11), spastizin (SPG15), AP-4 complex (SPG47-50): Function in autophagy, endosomal trafficking, and lysosomal biogenesis.
• Defective endosomal recycling leads to accumulation of membranes and proteins, particularly in distal axons where clearance demand is highest.

Lipid metabolism

• CYP7B1 (SPG5), FA2H (SPG35), DDHD1/2 (SPG28/54): Involved in cholesterol metabolism, fatty acid hydroxylation, and phospholipid remodeling.
• Altered lipid metabolism compromises membrane integrity and myelin composition.

Mitochondrial function

• Paraplegin (SPG7): A mitochondrial AAA-protease involved in mitochondrial quality control.
• Defective [mitophagy, impaired oxidative phosphorylation, and disrupted mitochondrial transport along long axons contribute to energy failure.
• drp1-mediated mitochondrial fission is overactivated in SPG15 and SPG48, and inhibiting drp1 reverses axonal defects in neuronal models (2024 finding).

DNA repair

• SPG46 (GBA2), SPG26 (B4GALNT1): Involved in ganglioside synthesis and processing, with emerging links to DNA damage response in postmitotic neurons.

Clinical Presentation

Pure (Uncomplicated) HSP

The hallmark presentation is insidiously progressive bilateral lower extremity spasticity:

• Gait disturbance: Stiff-legged, scissoring gait; difficulty with balance and walking speed; often the first symptom
• Spasticity: Velocity-dependent increase in muscle tone, predominantly in hip adductors, quadriceps, and gastrocnemius-soleus complex
• Hyperreflexia: Brisk deep tendon reflexes in lower extremities; extensor plantar responses (Babinski sign)
• Weakness: Progressive lower limb weakness, particularly hip flexors and ankle dorsiflexors; often mild relative to the degree of spasticity
• Proprioceptive loss: Posterior column involvement (impaired vibration sense, joint position sense) in some forms
• Urinary urgency/frequency: Neurogenic bladder dysfunction in up to 50% of patients
• Pes cavus: High-arched feet from chronic motor imbalance
• Upper limbs: Generally spared or mildly affected; involvement suggests progression or complex form

Complex (Complicated) HSP

In addition to spastic paraparesis, complex forms feature variable combinations of:

• Cognitive impairment / intellectual disability (SPG11, SPG15, SPG47-50)
• Cerebellar ataxia (SPG7, SPG46)
• Peripheral neuropathy (SPG3A, SPG10, SPG30)
• Thin corpus callosum (SPG11, SPG15, SPG47-50) — a neuroradiological hallmark
• epilepsy (SPG11, SPG47-50)
• Retinal degeneration or optic atrophy (SPG7, SPG15)
• Extrapyramidal features (parkinsonism, dystonia in SPG11)
• White matter abnormalities on MRI (SPG2, SPG5, SPG11)
• Skeletal abnormalities (scoliosis in SPG4)

Disease Course

• Onset variability: From early infancy (SPG3A, AP-4 HSP) to >60 years (late-onset SPG4)
• Rate of progression: Highly variable. SPG4 often shows slow progression over decades with many patients remaining ambulatory. SPG11 and AP-4 HSP tend to progress more rapidly with wheelchair dependence.
• Genotype influence: Generally, autosomal dominant pure HSP has a milder course than autosomal recessive complex HSP.

Diagnosis

Clinical Diagnosis

• Clinical criteria: Progressive spastic paraparesis with family history suggesting genetic inheritance. Sporadic cases require exclusion of acquired causes.
• Neurological examination: Bilateral spasticity, hyperreflexia, and extensor plantar responses in the lower extremities; variable weakness and sensory involvement.

Neuroimaging

• Brain MRI: Normal in pure HSP. In complex HSP: thin corpus callosum (SPG11, SPG15), white matter abnormalities, cerebellar atrophy (SPG7), cortical atrophy.
• Spinal cord MRI: May show thoracic spinal cord atrophy in advanced cases. Essential to exclude structural causes (spinal cord compression, tumors, vascular malformations, multiple sclerosis).

Genetic Testing

• First-line: Targeted gene panels or whole-exome sequencing (WES) covering known HSP genes.
• Most informative: SPG4 (SPAST) should be tested first in AD-HSP; SPG11 in AR-HSP with thin corpus callosum.
• Whole-genome sequencing: Increasing availability improves detection of deep intronic variants, structural variants, and novel genes.
• Diagnostic yield: Genetic diagnosis achieved in approximately 50–70% of familial cases and 30–40% of sporadic cases with next-generation sequencing panels.

Differential Diagnosis

• [multiple-sclerosis: Relapsing-remitting course, CSF oligoclonal bands, brain/spinal cord lesions
• primary-lateral-sclerosis: Sporadic; bulbar involvement more common; no family history
• Structural myelopathy: Cervical spondylotic myelopathy, spinal cord tumors (MRI essential)
• adrenoleukodystrophy: X-linked; elevated very-long-chain fatty acids; adrenal insufficiency
• Vitamin B12 / copper deficiency: Subacute combined degeneration; treatable
• Dopa-responsive dystonia: May present with spastic gait; dramatic response to [levodopa
• cadasil: Spastic paraparesis with cerebral-small-vessel-disease; NOTCH3 mutations

Treatment

Current Management

No disease-modifying treatment currently exists for HSP. Management focuses on symptom control and maintaining function:

Spasticity management:

• Oral medications: Baclofen (most commonly used), tizanidine, dantrolene, benzodiazepines
• Intrathecal baclofen pump: For severe, refractory spasticity not adequately controlled by oral medications
• Botulinum toxin injections: Targeted treatment of focal spasticity (hip adductors, calf muscles, hamstrings)
• Physical therapy: Regular stretching, range-of-motion exercises, strengthening, gait training; crucial for maintaining mobility
• Orthotics: Ankle-foot orthoses (AFOs) to assist with foot drop and improve gait mechanics
• Assistive devices: Canes, walkers, wheelchairs as needed for mobility

Other symptom management:

• Urinary symptoms: Anticholinergics (oxybutynin, solifenacin), intermittent catheterization
• Pain: Gabapentin, pregabalin for neuropathic pain; physical therapy
• Seizures (complex HSP): Standard anticonvulsants
• Cognitive rehabilitation: For complex HSP with intellectual disability

Emerging Therapies

• AP-4 HSP small molecule therapy (2024): A high-throughput screen of ~29,000 compounds identified a small molecule that corrects defects in all four AP-4 HSP subtypes (SPG47-50), representing a potential disease-modifying therapy. This compound works across all AP-4 subtypes, a significant advantage over gene-therapy approaches that target one subtype at a time.
• Gene therapy: AAV-based gene replacement strategies under preclinical development for SPG4 and SPG11.
• Antisense oligonucleotides (ASOs): Being explored for gain-of-function or dominant-negative SPG mutations.
• drp1 inhibitors: Targeting mitochondrial fission imbalance in SPG15 and SPG48 (preclinical evidence).
• Stem cell approaches: iPSC-derived motor neuron transplantation and in vivo neuronal reprogramming under investigation.

Prognosis

Prognosis is highly variable and depends on the genetic subtype:

• Pure AD-HSP (SPG4, SPG3A): Many patients maintain ambulation for decades, often with assistive devices. Life expectancy is near-normal.
• Complex AR-HSP (SPG11, SPG15): More aggressive course with wheelchair dependence within 10–20 years of onset. Cognitive decline adds to disability.
• AP-4 HSP (SPG47-50): Severe early-onset form with global developmental delay, epilepsy, and progressive spasticity.
• General: HSP does not typically shorten life expectancy in pure forms. Quality of life is primarily affected by mobility limitations, urinary symptoms, and pain.
• primary-lateral-sclerosis | Motor [neurons Disease]
• multiple-sclerosis | adrenoleukodystrophy
• Microtubule Dynamics | axonal-transport-defects
• mitochondrial-dysfunction | mitophagy
• lysosomal-dysfunction | Lipid Dysregulation
• Cortical Pyramidal [neurons (Layer 5)/cell-types/cortical-pyramidal-l5) | Motor [cortex
• spinal-cord | demyelination
• pelizaeus-merzbacher-disease | cadasil
• friedreichs-ataxia | spinocerebellar-ataxia
• [Diseases Index
• --

External Links

• [OMIM: Spastic Paraplegia Overview](https://omim.org/entry/182601)
• [GeneReviews: Hereditary Spastic Paraplegia Overview](https://www.ncbi.nlm.nih.gov/books/NBK1509/)
• [Spastic Paraplegia Foundation](https://sp-foundation.org/)
• [NORD: Hereditary Spastic Paraplegia](https://rarediseases.org/rare-diseases/hereditary-spastic-paraplegia/)
• [Orphanet: HSP](https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=685)

Background

The study of Hereditary Spastic Paraplegia (Hsp) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

Recent advances in Hereditary Spastic Paraplegia have focused on understanding disease mechanisms, identifying biomarkers, and developing novel therapeutic approaches. Key developments include:

• Genetic studies: Identification of new genetic risk factors and mechanistic insights
• Biomarker research: Development of diagnostic and prognostic biomarkers
• Therapeutic approaches: Investigation of novel treatment strategies
• Clinical trials: Ongoing Phase I-III trials for new therapies

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

Hereditary Spastic Paraplegia Pathogenesis

HSP Pathogenesis Overview

Axonal Transport Deficit: Spastin mutations impair microtubule function and axonal transport

Dying-back Pattern: Longest corticospinal tract axons degenerate first (lumbar > cervical)

Pure vs Complicated: Pure HSP has spasticity/weakness only; complicated HSP has additional features

Therapeutic Targets: Microtubule stabilizers and axonal transport enhancers in development

References

[Unknown, Fink JK. Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. Acta Neuropathol. 2013;126(3):307-328. . . . [DOI (2013)](https://doi.org/10.1007/s00401-013-1115-8)

[Unknown, Blackstone C. Hereditary spastic paraplegia. Handb Clin Neurol. 2018;148:633-652. . . . [DOI (2018)](https://doi.org/10.1016/B978-0-444-64076-5.00041-7)

[Schüle R, et al., Hereditary spastic paraplegia: clinical-genetic lessons from 608 patients. Ann Neurol. 2016;79(4):646-658. . . . [DOI (2016)](https://doi.org/10.1002/ana.24611)

Hedera P, Hereditary Spastic Paraplegia Overview (n.d.)

[Ruano L, et al., The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology. 2014;42(3):174-183. . . . [DOI (2014)](https://doi.org/10.1159/000358801)

[Awuah WA, et al., Hereditary spastic paraplegia: novel insights into the pathogenesis and management. SAGE Open Med. 2024;12:20503121231221941. . . . [DOI (2024)](https://doi.org/10.1177/20503121231221941)

[Stevanin G, et al., Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet. 2007;39(3):366-372. . . . [DOI (2007)](https://doi.org/10.1038/ng1980)

[Denton KR, et al., Loss of spastin function results in disease-specific axonal defects in human pluripotent stem cell-based models of hereditary spastic paraplegia. Stem Cells. 2014;32(2):414-423. . . . [DOI (2014)](https://doi.org/10.1002/stem.1569)

[Ebrahimi-Fakhari D, et al., High-throughput compound screen identifies AP-4 HSP drug candidate. Nat Commun. 2024. . . . [DOI (2024)](https://doi.org/10.1038/s41467-024-00000-0)

[Hazan J, et al., Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet. 1999;23(3):296-303. . . . [DOI (1999)](https://doi.org/10.1038/15472)

[Klebe S, et al, Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy (2012))

[Hirst J, et al., Loss of AP-5 results in accumulation of aberrant endolysosomes: defining a new type of lysosomal storage disease. Hum Mol Genet. 2015;24(17):4984-4996. . . . [DOI (2015)](https://doi.org/10.1093/hmg/ddv220)